Evidence map›Paper›PMID 26902783›Full record

ArticleHematology (Amsterdam, Netherlands)2016

C-C motif ligand 11 reduction in CLL patients serum after vitamin D supplementation.

Marcin Kubeczko, Elżbieta Nowara, Dobromiła Karwasiecka, Grażyna Siewior, Paulina Czajka-Francuz, Jerzy Chudek, Jerzy Wojnar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematology (Amsterdam, Netherlands), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Integrative Hematology: State of the Art.International journal of molecular sciences · 2023
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Marcin Kubeczkoa Clinical and Experimental Oncology Department , Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology , Gliwice Branch, Gliwice 44-400 , Poland.
Elżbieta Nowaraa Clinical and Experimental Oncology Department , Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology , Gliwice Branch, Gliwice 44-400 , Poland.
Dobromiła Karwasieckab Department of Internal Medicine and Oncological Chemotherapy, School of Medicine in Katowice , Medical University of Silesia , Katowice 40-027 , Poland.
Grażyna Siewiorb Department of Internal Medicine and Oncological Chemotherapy, School of Medicine in Katowice , Medical University of Silesia , Katowice 40-027 , Poland.
Paulina Czajka-Francuzb Department of Internal Medicine and Oncological Chemotherapy, School of Medicine in Katowice , Medical University of Silesia , Katowice 40-027 , Poland.
Jerzy Chudekb Department of Internal Medicine and Oncological Chemotherapy, School of Medicine in Katowice , Medical University of Silesia , Katowice 40-027 , Poland.
Jerzy Wojnarb Department of Internal Medicine and Oncological Chemotherapy, School of Medicine in Katowice , Medical University of Silesia , Katowice 40-027 , Poland.
Medical University of Silesia · PLThe Maria Sklodowska-Curie National Research Institute of Oncology · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVitamin D (VD) deficiency results in a worse prognosis in patients with chronic lymphocytic leukemia (CLL) and may affect the production of cytokines. Nonetheless, there is the lack of studies dealing with VD supplementation and its impact on chemokines in CLL patients.

aimThe primary endpoint of our interventional study was to evaluate the effect of cholecalciferol supplementation on serum chemokines levels in CLL patients. MATERIALS AND

methodsEighteen subjects with CLL were enrolled for the study. Six-month-long cholecalciferol supplementation was performed in CLL patients with serum 25-OH-D3 levels below 30 ng/ml. Cytokines levels were assessed at the beginning of the study and after 6 months. Baseline measurements of cytokines were compared to those in apparently healthy controls.

resultsIncreased levels of CCL2, CCL3, CCL4, CXCL8, CXCL10, TNFα, bFGF, G-CSF, and VEGF were found in CLL patients in comparison with the healthy controls. In the course of the VD supplementation a decrease in serum levels of chemokines CCL11, CCL3, and cytokine PDGF-BB was observed. The decrease of CCL11 was found in CLL patients on VD supplementation solely, whereas the decrease of CCL3 and PDGF-BB was observed in CLL subjects on both chemotherapy and VD supplementation.

conclusionThe VD supplementation may exert beneficial effect on chemokines levels in CLL patients with VD deficiency.

Indexed as

AgedChemokinesFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPrognosisVitamin DVitamin D DeficiencyChemokinesVitamin DChemokineChronic lymphocytic leukemiaVitamin D

Identifiers

PMID26902783
PMCPMC4960500
OpenAlexW2283148947

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.